Free Trial

Medicus Pharma (MDCX) Competitors

Medicus Pharma logo
$2.93 -0.09 (-2.98%)
As of 04:00 PM Eastern

MDCX vs. ENTA, LFVN, CCCC, ACOG, LYEL, IMRX, MOLN, LIMN, GLSI, and NKTX

Should you be buying Medicus Pharma stock or one of its competitors? The main competitors of Medicus Pharma include Enanta Pharmaceuticals (ENTA), Lifevantage (LFVN), C4 Therapeutics (CCCC), Alpha Cognition (ACOG), Lyell Immunopharma (LYEL), Immuneering (IMRX), Molecular Partners (MOLN), Liminatus Pharma (LIMN), Greenwich LifeSciences (GLSI), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry.

Medicus Pharma vs. Its Competitors

Enanta Pharmaceuticals (NASDAQ:ENTA) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Medicus Pharma had 4 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 6 mentions for Medicus Pharma and 2 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.45 beat Medicus Pharma's score of 0.39 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enanta Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Medicus Pharma
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Enanta Pharmaceuticals currently has a consensus price target of $18.00, indicating a potential upside of 143.24%. Medicus Pharma has a consensus price target of $23.50, indicating a potential upside of 702.05%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Medicus Pharma is more favorable than Enanta Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enanta Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Medicus Pharma
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.50

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 13.9% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 11.2% of Medicus Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Medicus Pharma has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -149.57%. Enanta Pharmaceuticals' return on equity of -79.83% beat Medicus Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Enanta Pharmaceuticals-149.57% -79.83% -26.65%
Medicus Pharma N/A -380.03%-224.22%

Medicus Pharma has lower revenue, but higher earnings than Enanta Pharmaceuticals. Medicus Pharma is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enanta Pharmaceuticals$67.64M2.34-$116.04M-$4.54-1.63
Medicus PharmaN/AN/A-$11.16M-$1.16-2.53

Summary

Enanta Pharmaceuticals beats Medicus Pharma on 8 of the 15 factors compared between the two stocks.

Get Medicus Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDCX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDCX vs. The Competition

MetricMedicus PharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$40.99M$3.03B$5.74B$9.51B
Dividend YieldN/A2.40%4.60%3.99%
P/E Ratio-2.5321.1828.1120.03
Price / SalesN/A339.44461.57200.15
Price / CashN/A43.2336.5559.01
Price / Book10.108.368.655.90
Net Income-$11.16M-$55.19M$3.25B$258.66M
7 Day Performance-5.79%5.89%4.20%2.23%
1 Month Performance7.33%17.63%10.82%12.76%
1 Year PerformanceN/A5.09%34.70%19.36%

Medicus Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDCX
Medicus Pharma
2.3288 of 5 stars
$2.93
-3.0%
$23.50
+702.0%
N/A$40.99MN/A-2.53N/AUpcoming Earnings
ENTA
Enanta Pharmaceuticals
3.931 of 5 stars
$7.73
+0.8%
$18.00
+132.9%
-51.1%$163.96M$67.64M-1.70160Positive News
LFVN
Lifevantage
4.2567 of 5 stars
$13.86
+6.9%
$30.50
+120.1%
+101.7%$163.27M$200.16M20.09260Positive News
Gap Down
CCCC
C4 Therapeutics
2.8704 of 5 stars
$2.42
+9.0%
$12.00
+395.9%
-61.4%$157.64M$35.58M-1.65150Upcoming Earnings
ACOG
Alpha Cognition
1.7311 of 5 stars
$9.99
+1.9%
$20.00
+100.2%
N/A$156.99MN/A-8.32N/A
LYEL
Lyell Immunopharma
2.5117 of 5 stars
$10.99
+6.9%
$15.00
+36.5%
-67.7%$152.23M$60K-0.44270News Coverage
Gap Up
IMRX
Immuneering
3.1424 of 5 stars
$4.10
-2.8%
$13.25
+223.2%
+247.8%$151.86M$320K-2.0960
MOLN
Molecular Partners
2.5708 of 5 stars
$3.89
+4.3%
$12.00
+208.5%
-38.4%$150.67M$5.65M-2.03180News Coverage
Gap Up
LIMN
Liminatus Pharma
N/A$6.47
+11.9%
N/AN/A$150.37MN/A0.00N/ANews Coverage
Gap Down
High Trading Volume
GLSI
Greenwich LifeSciences
2.2011 of 5 stars
$11.49
+3.1%
$39.00
+239.4%
-26.1%$148.92MN/A-9.123
NKTX
Nkarta
1.7718 of 5 stars
$2.23
+7.2%
$14.33
+542.8%
-67.8%$147.59MN/A-1.48140

Related Companies and Tools


This page (NASDAQ:MDCX) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners